Borregaard ASA BRG
Oslo Børs · Basic Materials · Specialty Chemicals
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Guidance from Borregaard
BetaWhat the company says it expects, and how often it has delivered on it.
Guidance in the latest report
- BioSolutions sales volume (FY 2026)
“For BioSolutions, sales volume for 2026 is forecast to be 335,000 tonnes.” (p. 12) - BioSolutions sales volume (Q3 2026)
“Sales volume in the 3rd quarter is expected to be approximately 85,000 tonnes.” (p. 12) - BioMaterials sales volume to exceed 160,000 tonnes (FY 2026)
“For BioMaterials, sales volume is forecast to exceed 160,000 tonnes in 2026.” (p. 12) - BioMaterials sales volume (Q3 2026)
“In the 3rd quarter, sales volume is expected to be approximately 40,000 tonnes.” (p. 12) - BioMaterials volume of highly specialised grades higher than 2025 (FY 2026)
“Sales volume of highly specialised grades is expected to be higher than in 2025.” (p. 12) - Bioethanol sales prices largely in line with 2025 (FY 2026)
“Sales prices for bioethanol are expected to be largely in line with 2025.” (p. 12) - Fine chemical intermediates sales volume increase vs 2025 (FY 2026)
“Sales volume for fine chemical intermediates is expected to increase compared with 2025.” (p. 12) - Lower bioethanol deliveries and weaker product mix for fine chemical intermediates in H2 vs H1 (H2 2026)
“Deliveries of bioethanol are expected to be lower, and the product mix for fine chemical intermediates will be weaker in the 2nd half of 2026 compared with the 1st half of the year.” (p. 12) - Wood costs lower in H2 2026 vs H1 2026 (H2 2026)
“Borregaard's wood costs in the 2nd half of 2026 are expected to be 3-4% lower compared with the 1st half of 2026.” (p. 12) - Cost improvement programme, annual cost savings, full effect from 2028 (2028)
“Borregaard is implementing a cost improvement programme targeting annual cost savings of NOK 150 million.” (p. 12) - Net FX impact on EBITDA vs Q3 2025 (Q3 2026)
“Borregaard expects a net impact of foreign exchange on EBITDA1 of approximately NOK 10 million in the 3rd quarter of 2026” (p. 9) - Net FX impact on EBITDA vs 2025 (FY 2026)
“approximately NOK 10 million in the 3rd quarter of 2026 and NOK 45 million for the full year of 2026, compared with the corresponding periods in 2025.” (p. 9)
Guidance against the outcome
| Given | What | Period | Guided | Actual | Outcome |
|---|---|---|---|---|---|
| 2022-10-21 | Revenue In BioMaterials, the average price in sales currency is expected to increase 4-6% in... |
Q4 2022 | 4.0 % – 6.0 % | 22.4 % | Above |
| 2021-07-15 | Revenue Sales growth will continue for cellulose fibrils, and new business development and... |
2021 | Up (from 3,990) | 5,805 | Met |
| 2021-02-03 | Revenue In BioMaterials, the average price in sales currency is expected to be 2-3% below the... |
2021 | Down (from 3,990) | 5,805 | Above |
| 2016-07-18 | Revenue In 2016, average cellulose price in sales currency is expected to be approximately 2%... |
2016 | Down (from 4,164) | 1,113 | Met |
| 2016-02-03 | Revenue average cellulose price in sales currency are expected to be approximately 3% below... |
2016 | Down (from 4,164) | 1,113 | Met |
Amounts in NOK million. Each outcome counts from the day the report with the actual figure was published, as a backtest sees it. Hover a metric for the report's own words; click the date or the actual figure to open the report on its page.
Guidance only counts when it names a year or quarter and a figure the reports show: revenue, operating profit, margins, EPS and bank and insurance ratios. Read by an AI model and can be wrong. Not investment advice.
Not investment advice. Figures may contain errors from the data source.